4.5 Article

Characterization of AKT Somatic Mutations in Chinese Breast Cancer Patients

期刊

CANCER MANAGEMENT AND RESEARCH
卷 13, 期 -, 页码 3055-3065

出版社

DOVE MEDICAL PRESS LTD
DOI: 10.2147/CMAR.S299624

关键词

AKT; next-generation sequencing; breast cancer; somatic mutations; population study

类别

资金

  1. High-level Hospital Construction Project [DFJH201921]
  2. National Natural Science Foundation of China [81902828, 82002928]
  3. Natural Science Foundation of Guangdong Province [2016A030313768, 2018A030313292]
  4. Guangzhou Municipal Science and Technology Project [201707010418, 201804010430]
  5. Fundamental Research Funds for the Central Universities [y2syD2192230]
  6. Medical Scientific Research Foundation of Guangdong Province [B2019039]
  7. Doctor Launch Fund of Guangdong Provincial People's hospital [2018bq02, 2020bq11]

向作者/读者索取更多资源

The study aimed to investigate AKT gene mutation status in Chinese breast cancer patients through next-generation sequencing and immunohistochemistry staining. The patients in GDPH cohort showed higher rates of certain clinicopathological characteristics and AKT1 mutation, but lower rates of overall AKT and AKT3 mutation compared to the TCGA cohort. Missense mutation and copy number amplification were identified as the most common AKT variation types in GDPH and TCGA cohorts, respectively.
Purpose: This study aimed to investigate AKT gene mutation status in Chinese breast cancer patients. Methods: The study included 411 breast cancer patients hospitalized in Guangdong Provincial People's Hospital (GDPH) from June 1, 2017 to September 27, 2018. Mastectomy or breast conserving surgery was performed, and tissue samples were subjected to next-generation sequencing (NGS) to determine AKT gene mutation status. Meanwhile, the expression of human epidermal growth factor receptor 2 (Her2), progesterone receptor (PR), and estrogen receptor (ER) was analyzed by immunohistochemistry staining. The Cancer Genome Atlas (TCGA) database was used for comparative studies. Results: Patients in the GDPH cohort had an older age (P < 0.001), higher postmenopausal rate (P < 0.001), larger tumor size (P < 0.001), higher histologic type of infiltrating duct cancer (P < 0.001), higher metastatic rate (P < 0.001), higher expression of ER (P = 0.015) and HER2 (P < 0.001), and higher percentage of the HR/HER2 subtype (P < 0.001) than those in the TCGA cohort. The GDPH cohort displayed lower rates of overall AKT and AKT3 mutation (P < 0.001), but a higher AKT1 mutation rate (P < 0.0001) compared with the TCGA cohort. Notably, the NGS studies identified missense mutation and copy number amplification as the most common AKT variation type in the GDPH and TCGA cohorts, respectively. Specifically, E17K mutation in AKT1 was predominantly detected in GDPH cohort, while being absent in TCGA cohort. Moreover, in the GDPH cohort, AKT variation was correlated with a number of clinicopathological variables, including age over 50, HER2-, HR+/HER2-, and PR+. Conclusion: Patients in the GDPH cohort had lower rates of AKT and AKT3 mutation and higher AKT1 mutation rate than those in the TCGA cohort, while harboring missense mutations detected predominantly as E17K mutation in AKT1. In GDPH cohort, there were correlations between AKT mutation and the clinicopathological characteristics of patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据